PHGE BiomX Inc

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

NESS ZIONA, Israel, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, November 9, 2022, at 8:00 a.m. ET, to report third quarter 2022 financial results and provide business updates.

To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at .

About BiomX

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at , the content of which does not form a part of this press release.

BiomX, Inc.

Anat Primovich

Corporate Project Manager



 

Investor Relations:

LifeSci Advisors, LLC

John Mullaly

 

Source: BiomX Inc



EN
02/11/2022

Underlying

PHGEBiomX Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BiomX Inc

 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) NESS ZIONA, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will present at the Biomed Israel 2025 conference, reviewing the Company’s toplin...

May 19, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Reports First Quarter 2025 Financial Results and Provides Busine...

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on track to report topline results in Q1 2026 In April 2025, shareholders approved exercise of warrants issued in $12 million in financings announced in February 2025; funds expected to provide runway through topline Phase 2b results for BX004 trial The Company will host a conference call and webcast today...

May 15, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX to Host First Quarter 2025 Financial Results Conference Call and...

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, pleas...

May 8, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Discl...

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's indepe...

April 1, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating...

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reduci...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch